Liu Jinlu, Wu Wenbi, Zhu Qing, Zhu Hong
Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Pharmaceutics. 2023 Oct 4;15(10):2421. doi: 10.3390/pharmaceutics15102421.
Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest malignancies worldwide, is characteristic of the tumor microenvironments (TME) comprising numerous fibroblasts and immunosuppressive cells. Conventional therapies for PDAC are often restricted by limited drug delivery efficiency, immunosuppressive TME, and adverse effects. Thus, effective and safe therapeutics are urgently required for PDAC treatment. In recent years, hydrogels, with their excellent biocompatibility, high drug load capacity, and sustainable release profiles, have been developed as effective drug-delivery systems, offering potential therapeutic options for PDAC. This review summarizes the distinctive features of the immunosuppressive TME of PDAC and discusses the application of hydrogel-based therapies in PDAC, with a focus on how these hydrogels remodel the TME and deliver different types of cargoes in a controlled manner. Furthermore, we also discuss potential drug candidates and the challenges and prospects for hydrogel-based therapeutics for PDAC. By providing a comprehensive overview of hydrogel-based therapeutics for PDAC treatment, this review seeks to serve as a reference for researchers and clinicians involved in developing therapeutic strategies targeting the PDAC microenvironment.
胰腺导管腺癌（PDAC）是全球最致命的恶性肿瘤之一，其肿瘤微环境（TME）的特征是包含大量成纤维细胞和免疫抑制细胞。PDAC的传统治疗方法常常受到药物递送效率有限、免疫抑制性TME以及不良反应的限制。因此，迫切需要有效且安全的疗法来治疗PDAC。近年来，水凝胶凭借其出色的生物相容性、高药物负载能力和可持续释放特性，已被开发为有效的药物递送系统，为PDAC提供了潜在的治疗选择。本综述总结了PDAC免疫抑制性TME的独特特征，并讨论了基于水凝胶的疗法在PDAC中的应用，重点关注这些水凝胶如何重塑TME并以可控方式递送不同类型的药物。此外，我们还讨论了潜在的候选药物以及基于水凝胶的PDAC疗法面临的挑战和前景。通过全面概述基于水凝胶的PDAC治疗方法，本综述旨在为参与开发针对PDAC微环境的治疗策略的研究人员和临床医生提供参考。
